Healthcare Shifts to AI-Native Models as Hims & Hers and Novo Nordisk Expand Integration
From personalized weight loss coaching to streamlined drug discovery, industry leaders are embedding AI into the core of patient care and R&D.
The healthcare sector is moving beyond using artificial intelligence as a peripheral tool, transitioning instead toward "AI-native" systems that embed automation into the core of patient care and pharmaceutical research. Recent initiatives from Hims & Hers and Novo Nordisk illustrate this shift, targeting both the consumer experience and the industrial pipeline.
Hims & Hers has launched a new AI-native care experience specifically for members of its Hers weight loss program. The app provides users with personalized guidance and real-time progress tracking, designed to facilitate a proactive, doctor-led approach to weight management. By integrating AI directly into the member journey, the company aims to move away from reactive care toward a more continuous, data-driven support model.
Optimizing the Pharmaceutical Pipeline
On the industrial side, pharmaceutical giant Novo Nordisk has entered a strategic partnership with provider-data company H1 to overhaul its research and development operations. The collaboration focuses on developing AI models to optimize drug discovery, clinical trial design, enrollment, and the selection of trial sites. As part of the agreement, H1 will acquire the rights to develop StudyHub, Novo Nordisk's digital platform dedicated to clinical development.
This move is part of a broader strategy by Novo Nordisk to diversify its AI capabilities. The company has already established a network of collaborations with technology leaders, including LLM provider OpenAI, hardware giant NVIDIA, and Valo Health, to address operational inefficiencies across its portfolio.
The Impact on Industry and Patients
These developments signal a fundamental change in how healthcare is delivered and developed. For consumers, the shift toward AI-native apps means a transition from static medical advice to real-time, personalized health coaching that can adapt to a patient's daily progress. This reduces the friction between clinical visits and daily health management.
For the pharmaceutical industry, the stakes are financial and temporal. Drug development is traditionally a decade-long process costing billions of dollars. By using AI to refine site selection and study design, companies can significantly reduce the time and capital required to bring new therapies to market. This wave of AI is intended to help the company reduce cycle times and improve decision-making across the development lifecycle.
Future Outlook
As these AI-native frameworks scale, the industry will be watching whether these efficiencies translate into lower costs for patients and faster access to life-saving medications. While the integration of AI into clinical workflows is accelerating, the long-term efficacy of AI-led patient management and the actual reduction in drug development timelines remain the primary metrics for success in the coming years.